Trial Profile
Pilot Phase II Study of 5-Azacytidine in Previously Treated Patients With Advanced NSCLC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics; Pharmacogenomic
- 16 Sep 2019 Status changed from active, no longer recruiting to completed.
- 12 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 19 Nov 2012 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.